A DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTRE, RANDOMISED PHASE III STUDY OF DISEASE-RELATED SYMPTOMS COMPARING ZD1839 (IRESSA)(250MG TABLET) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN SYMPTOMATIC PATIENTS WITH ADVANCED NSCLC WHO HAVE RECEIVED ONE OR TWO PRIOR CHEMOTHERAPY REGIMENS AND ARE REFRACTORY OR INTOLERANT TO THEIR MOST RECENT REGIMENS

Study identifier:1839IL/0710

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTRE, RANDOMISED PHASE III STUDY OF DISEASE-RELATED SYMPTOMS COMPARING ZD1839 (IRESSA)(250MG TABLET) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN SYMPTOMATIC PATIENTS WITH ADVANCED NSCLC WHO HAVE RECEIVED ONE OR TWO PRIOR CHEMOTHERAPY REGIMENS AND ARE REFRACTORY OR INTOLERANT TO THEIR MOST RECENT REGIMENS

Medical condition

lung cancer

Phase

Phase 3

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Mar 2004
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria